Shares of GT Biopharma cratered for a second straight session, trading at $7.99 — down 11.2% — as investors continued to punish the micro-cap biotech for a deeply discounted convertible financing deal that could dramatically expand the number of shares outstanding and shrink each existing investor's ownership stake. GT Biopharma's Discounted Stock Deal Raises Cash but May Drown Existing Shareholders — Is This a Survival Move or a Value Trap?
Shares of GT Biopharma tumbled for a second consecutive day, hitting $7.99 — down 11.2% — after a punishing 22.6% drop the prior session, as investors recoiled from a deeply discounted financing deal that could flood the market with new shares and shrink existing holders' stakes.
• The Deal Gives New Investors a Built-In Discount — and Existing Shareholders Pay the Price. On September 14, GT Biopharma sold up to 8,277 shares of Series M 10% Convertible Preferred Stock and warrants for $7.45 million, with each preferred share convertible into common stock at $6.10 — roughly 24% below the current $7.99 price. That means new investors can convert and immediately profit, while the wave of new common shares dilutes everyone else's ownership. Warrants equal to 100% of the conversion shares, plus additional "greenshoe" warrants, roughly double the dilution threat. At $6.10 per share, the base conversion alone could create over 1.35 million new common shares, and the warrants could double that figure.
• The Company Was Running on Fumes. GT Biopharma reported just $5.1 million in cash as of June 30, 2026, which it said would last only through Q4 2026.
The company posted operating income of -$12.4 million and net income of -$28.4 million, with diluted losses of $6.68 per share. With zero revenue, the $7.45 million raise looks less like a strategic choice and more like a survival necessity — taken at unfavorable terms because management had little leverage.
• Two Early-Stage Drug Trials Aren't Enough to Justify the Risk. GT Biopharma is running an early-stage trial of its cancer-fighting immune cell technology in blood cancers, now enrolling its fifth group of patients.
A second trial targeting solid tumors began in May 2026. Both are Phase 1 — meaning they test whether the drugs are safe, not whether they work. Commercial revenue is years away, if it arrives at all.
• A Pattern of Dilution Has Already Eroded Long-Term Holders. GT Biopharma recently filed to register 9.7 million common shares for resale from prior preferred stock and warrant conversions.
Over five years, the company's market value has shrunk at an average rate of -27.16% per year.
The stock had surged 122% in the week before the deal , suggesting management capitalized on a brief price spike — rational for the company, brutal for anyone who bought into the rally.